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Though rare diseases affect fewer patients than common
diseases, developing drugs for them is subject to the
same principles. But constructing and leading rare dis-
eases clinical trials means also facing numerous difficul-
ties which are more important in this field
(methodology, little knowledge of the disease’s evolution,
choice of the judgment’s criteria, small population’s size,
logistical matters...)
However during the last decade, France led several
initiatives to improve the burden of rare diseases. Cen-
tres of Expertise were identified, ability centres have
been appointed and a National Plan for rare diseases
was developed.
Nevertheless, in spite of the great dynamic created by
France, development and availability of orphan thera-
peutics remain problematic regarding rare diseases spe-
cificities. In this context, it is important to gather skills
and strengths to make patients benefit from fundamen-
tal research’s results and accelerate clinical trials.
Orphandev is a French Clinical Trials Network based
on a strong collaboration principle with all actors
involved (academics, industries and patients) dedicated
to orphan drugs development. It was created by aca-
demics to help academics but also others actors involved
in rare diseases’ research. The Network’ skills have
already been dedicated to orphan drugs’ trials: Charcot
Marie Tooth (2004), Rett (2006) and Progeria (2008).
Orphandev has intervened according to the mutualisa-
tion and translational research concepts from the
experimental phase (in vitro and animals’ tests) to the
results’ valorisation with every single actor involved in
the study. With the experience gained and the successful
results, we have developed an organisational concept in
order to capitalise on the lessons learnt and optimise
the trials process.
In a time of great therapeutics development with solu-
tions coming from gene breakthroughs but not only,
Orphandev allows for further improvement of the inter-
face between fundamental research, clinical research and
drug developments in rare diseases in a more opera-
tional way.
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